Angela Dispenzieri, M.D., conducts research in plasma cell disorders, including multiple myeloma, amyloidosis, POEMS syndrome and other rare plasma cell disorders.
Dr. Dispenzieri's joint appointments in hematology and clinical chemistry are conducive to clinical and translational research in these fields. She also specializes in clinical trials and stem cell transplantation.
- Application of mass spectrometry to the diagnosis and prognosis of patients with plasma cell disorders. In collaboration with specialists in laboratory medicine, the proteomics core and bioinformatics, Dr. Dispenzieri examines immunoglobulins found in tissues, blood and urine and the impact they have in diseases involving clonal plasma cells.
- Immunoglobulin light chain (AL) amyloidosis. A major focus of Dr. Dispenzieri's research is the optimization of treatments and prognostic markers that are of value to patients with AL amyloidosis. She works closely with physicians and scientists in other specialty areas to devise better ways to care for patients with AL amyloidosis.
- POEMS syndrome. Dr. Dispenzieri's work has been instrumental in dissecting the features and underpinnings of POEMS syndrome and designing better treatments for patients with this very rare plasma cell disorder. Her studies cross many disciplines to harvest the expertise required to treat patients with POEMS syndrome.
- Multiple myeloma. Dr. Dispenzieri conducts innovative trials to treat multiple myeloma.
Significance to patient care
Dr. Dispenzieri's research is highly translational and impactful because understanding disease pattern is instrumental to improving patient care.